Toronto, Ontario – TheNewswire - August 26, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT) announces a non-brokered private placement of up to CDN$500,000 (the “ Offering ”) of unsecured convertible debenture units (“ Units ”) subject to TSXV Venture Exchange (the “ Exchange ”) acceptance. Each Unit will be comprised of one (1) unsecured convertible debenture principal amount of... Read More

Toronto, Ontario – TheNewswire - August 18, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, ) ( TSXV:VPT; OTC:VPTDF) a leader in AI-powered heart analysis solutions, is pleased to announce the appointment of Thomas Brown , former Vice President of North American Sales at Intelligent Ultrasound, as Director of the Congenital Heart Defect (CHD) Program . Mr. Brown brings more than 20 years of... Read More

Toronto, Ontario – TheNewswire - August 15, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT; OTC:VPTDF) a leader in AI-powered heart analysis solutions, today announced the launch of a targeted marketing program focused on the diagnosis and monitoring of congenital heart defects (CHD). The initiative is designed to solidify Ventripoint’s leadership position in this high-need... Read More

Toronto, Ontario – TheNewswire - July 28, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT; OTC:VPTDF) is pleased to announce that it has received the first purchase order from Lishman Global Inc. for VMS+ technology to be used within its echocardiography image platform in the People’s Republic of China. Lishman will use the technology within six hybrid echocardiography systems built... Read More

Toronto, Ontario – TheNewswire - July 11, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT) is pleased to announce that it has signed a non-binding term sheet with Lishman Global Inc. outlining the exclusive , non-transferable license of Ventripoint technology for use within Lishman’s echocardiography image platform in the People’s Republic of China including the Special... Read More

Toronto, Ontario – TheNewswire - June 30, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, ( TSXV:VPT) announces it will satisfy debenture interest payment obligations with the issuance of common shares, subject to TSX Venture Exchange (“ TSXV ”) approval. The Corporation will issue an aggregate of 564,473 common shares (“ Shares ”) for the payment of an aggregate of $76,203.59 of interest owing... Read More

Toronto, Ontario – TheNewswire - June 17, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it has entered into an advisory agreement with Fournel Advisory (“Fournel”) to provide the Company with financial advisory, business development and M&A services for one year to accelerate the commercialization of Ventripoint’s AI-powered, heart-scanning technology.... Read More

Toronto, Ontario – TheNewswire – June 17, 2025 - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”) (TSXV:VPT, OTC:VPTDF) is providing an update on options. On March 12, 2025, the Corporation issued 500,000 option grants at $0.15 and 500,000 option grants at $0.20 to contractors to the Corporation. These option grants vested over 4 months and had a term of two years. On June 2, 2025, the Corporation issued... Read More

Toronto, Ontario – TheNewswire – May 28, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce its participation in the 58th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC) being held on May 28th-31st 2025 in Hamburg, Germany. The AEPC is a network of specialists committed to the practice and advancement of Congential... Read More

Toronto, Ontario – TheNewswire - April 30, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) has increased the depth of its commercial experience with the addition of Stuart Gall to the company's Business Advisory Board to provide advice and guidance on the commercialization of Ventripoint’s AI-powered, heart-scanning technology by hospitals and clinics around the world. With its... Read More

Toronto, Canada — April 10, 2025 — TheNewswire - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) , a leading provider of innovative cardiac diagnostic solutions, is pleased to provide a shareholder update. Dear Shareholders , With the conclusion of the first quarter we are pleased to provide an update on advancements at Ventripoint and to express our ongoing appreciation for your support.... Read More

Toronto, Ontario – TheNewswire - April 8, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) today announced that it has appointed Nic Coutin, PhD. to oversee Clinical Affairs. In this role he will be providing leadership to the Company’s ongoing research, translational science, and clinical studies. Nicolas will report directly to Hugh MacNaught, President and CEO. Dr. Coutin was... Read More

Toronto, Ontario, April 3, 2025 – TheNewswire - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) announces that it has made an application to the TSX Venture Exchange (the “ TSXV ”) to extend the expiry date of a total of 2,845,771 common share purchase warrants (the “ Warrants ”) exercisable at $0.30. The Warrants were originally issued by the Company in connection with a private... Read More

Toronto, Ontario – TheNewswire - March 24, 2025 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) is pleased to announce the release of a whitepaper comparing the performance of the VMS+™4.0 advanced Automated Radiological Image Processing Software/System to the previous basic model, VMS+ 3.0. This latest advancement of Ventripoint’s proprietary technology, VMS+ 4.0 , which recently... Read More

Toronto, Ontario, March 21, 2025 – TheNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces the closing of its previously announced (see press release of March 14, 2025) non-brokered private placement (the “ Offering ”) of unsecured convertible debenture units (“ Units ”), subject to final TSXV Venture Exchange (the “ Exchange ”) acceptance. The Corporation has issued 500 Units... Read More

Toronto, Ontario – TheNewswire - March 14, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT) announces a non-brokered private placement of up to CDN$500,000 (the “ Offering ”) of unsecured convertible debenture units (“ Units ”) subject to TSXV Venture Exchange (the “ Exchange ”) acceptance. Each Unit will be comprised of one (1) unsecured convertible debenture principal amount of... Read More

To ronto, Ontario - TheNewswire - February 27, 2025 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for the VMS+™ 4.0 Automated Radiological Image Processing Software/System. This latest advancement of Ventripoint’s proprietary technology, VMS+ 4.0 , delivers a number of... Read More

Toronto, Ontario – TheNewswire – February 11, 2024 - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”)(TSXV:VPT, OTC:VPTDF) announces that on January 20, 2025, the Corporation granted an aggregate of 4,015,000 options to directors, officers, employees, contractors and consultants of the Corporation with an exercise price of $0.10 and terms of between 2 (two) to 10 (ten) years, vesting from immediately to... Read More

Toronto, Ontario – TheNewswire - February 10, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, ( TSXV:VPT) announces, further to its press release dated December 17, 2024 and January 20, 2025 announcing the closing of the first and second tranches of its non-brokered private placement (see November 6, 2024, December 9, 2024, December 17, 2024 and December 20, 2024 press releases) (the “ Offering... Read More

Toronto, Ontario – TheNewswire - January 30, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) has significantly bolstered its commercial capability with the addition of Karl Pringle to the company's Business Advisory Board, to accelerate sales of Ventripoint’s AI-powered, heart-scanning technology by hospitals and clinics around the world. With its proprietary VMS+ platform,... Read More

Toronto, Canada — TheNewswire –-- January 23, 2025 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) , a leading provider of innovative cardiac diagnostic solutions, is pleased to provide a shareholder update. Dear Shareholders , Further to the update that was provided in December I am pleased to share our outlook and objectives for 2025. Technology and Product Development Last year... Read More

Updates to submission of VMS+ 4.0 provided to FDA on January 17, 2025 Ventripoint will market new advances in USA after FDA clearance Toronto, Ontario – TheNewswire - January 21, 2025 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) has reached another development milestone by updating the submission of its next generation of software, VMS+ 4.0, to the U.S. Food and Drug... Read More

Toronto, Ontario – TheNewswire - January 20, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT) announces, further to its press release dated December 17, 2024 announcing the closing of the first tranche of its non-brokered private placement (see November 6, 2024, December 9, 2024, December 17, 2024 and December 20, 2024 press releases) (the “ Offering ”) of unsecured convertible... Read More

Toronto, Ontario, Dec 20, 2024 – TheNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces that it will seek approval of TSX Venture Exchange (“ TSXV ” or the “ Exchange ”) to extend its previously announced non-brokered private placement (“ Offering ”) of unsecured convertible debentures (“ Debentures ”). (See press releases dated November 6, 2024, December 9, 2024 and December... Read More

Toronto, Ontario – TheNewswire - December 18, 2024 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTCQB:VPTDF) is pleased to announce Ventripoint and ASCEND Cardiovascular, a leading provider of cardiovascular IT solutions, have signed a term sheet defining the general terms and conditions for a non-exclusive license to Ventripoint’s VMS+ proprietary technology. The two parties expect to execute... Read More

Toronto, Ontario, December 17, 2024 – TheNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces that it has closed the first tranche of its previously announced (see November 6, 2024 and December 9, 2024 press releases) amended non-brokered private placement of unsecured convertible debentures (“ Debentures ”). Ventripoint has issued an aggregate of $341,000 principal amount of... Read More

Toronto, Ontario, December 9, 2024 – Th eNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces it will satisfy debenture interest payment obligation with the issuance of common shares, subject to TSX Venture Exchange (“ TSXV ”) approval. The Corporation will issue an aggregate of up to 112,210 common shares (“ Shares ”) for the payment of an aggregate of $11,221 of interest on... Read More

Toronto, Canada – TheNewswire - December 4, 2024 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTCQB:VPTDF) , a leading provider of innovative cardiac diagnostic solutions, is pleased to provide a shareholder update. Dear Shareholders , As we move towards year end we’re excited to share some significant advancements and updates from Ventripoint and to share our gratitude for your continued... Read More

Toronto, Ontario – TheNewswire - November 19, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTCQB:VPTDF) today announced the creation of a new sales program aimed at expanding its presence in the United States in 2025. This innovative program is designed to accelerate the adoption of the company's AI-powered echocardiography solutions, which are transforming cardiovascular care by... Read More

Toronto, Ontario – TheNewswire - November 14, 2024 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT) announces it has closed the second and final tranche of its non-brokered private placement offering, as described in its press releases of August 28, 2024, August 29, 2024, September 17, 2024, October 15, 2024, and October 18, 2024 pursuant to the listed issuer financing exemption under... Read More

Toronto, Ontario – TheNewswire - November 6, 2024 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT) announces that it intends to complete, subject to TSXV Venture Exchange (the “ Exchange ”) acceptance, an amended non-brokered private placement of up to CDN$1,000,000 (the “ Offering ”) of unsecured convertible debentures (“ Debentures ”). Debentures issued pursuant to the Offering will be... Read More

Toronto, Ontario – TheNewswire - October 24, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTCQB:VPTDF) a leader in whole heart analysis technology, is pleased to announce CE Mark certification for its latest offering, VMS+4.0. This marks a significant milestone for Ventripoint as it continues to innovate and provide cutting-edge solutions to healthcare professionals worldwide. The... Read More

ronto, Ontario – TheNewswire - October 18, 2024 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT) announces that it has closed the first tranche of its non-brokered private placement offering, as described in its press releases of August 28, 2024, August 29, 2024, September 17, 2024, and October 15, 2024 pursuant to the listed issuer financing exemption under Part 5A of NI 45-105 - Prospectus... Read More

Toronto, Ontario – TheNewswire - October 15, 2024 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT) announces that it has received approval of TSX Venture Exchange (“ TSXV ” or the “ Exchange ”) to extend its previously announced non-brokered private placements of up to $3,000,000 of unsecured convertible debentures (“ CD Offering ”) and up to $500,000 (the “ LIFE Offering ”) of units (“... Read More

Toronto, Ontario - TheNewswire - (October 11, 2024) - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTCQB:VPTDF) is pleased to announce that it has submitted its next generation of software and hardware, VMS+4.0, for approval under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Company has received notification its submission is complete and is... Read More

Toronto, Ontario – TheNewswire - October 8, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTCQB:VPTDF) is pleased to announce the successful completion of three important quality audits, which were required to continue sales of the existing VMS+ models as well as to submit the newest version, VMS+4.0, for European Union review. All audits resulted in positive outcomes and demonstrated... Read More

Toronto, Canada --- TheNewswire — September 30, 2024 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTCQB:VPTDF) , a leading provider of innovative cardiac diagnostic solutions, is pleased to announce the U.S.-based Ollie Hinkle Heart Foundation will highlight Ventripoint's AI-powered heart imaging technology at the opening session of the Take Heart Conference: Turning Limitations Into... Read More

Toronto, Ontario, September 20, 2024 – Th eNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces that it has closed the first tranche of its previously announced (see August 28, 2024 press release) non-brokered private placement of unsecured convertible debentures (“ Debentures ”) for gross proceeds of $300,000. Ventripoint has issued an aggregate of $300,000 principal amount of... Read More

Toronto, Ontario – TheNewswire - September 17, 2024 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT) announces, further to its press release dated August 29, 2024, that it has filed an amended and restated Offering Document in connection with its non-brokered private placement financing of up to CDN$500,000 (the “ Offering ”) of units (“ Units ”) of the Corporation at price of $0.195 per... Read More

Toronto, Ontario – TheNewswire – September 9, 2024 - TheNewswire - Ventripoint Diagnostics Ltd. ( “ Ventripoint ” or the “ Corporation ”)(TSXV:VPT, OTCQB:VPTDF) announces that on September 6, 2024, the Corporation granted an aggregate of 2,917,000 options to directors, officers, employees, contractors and consultants of the Corporation with an exercise price of between $0.175 and $0.20 and terms of 1 (one) to 10 (ten) years.... Read More

Toronto, Canada — TheNewswire -- September 9, 2024 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTCQB:VPTDF) , a leading provider of innovative cardiac diagnostic solutions, is pleased to announce the launch of its new reference site programme. This initiative aims to foster collaboration with key stakeholders in major hospitals to enhance the accuracy, efficiency and diagnostic capabilities of... Read More

Re-issue at the request of the TSX Venture Exchange Toronto, Ontario – TheNewswire - September 9, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTCQB:VPTDF) announces it has entered into an investor relations agreement (the “IR Agreement”) with Empire Relations Group Inc . (“ERG”). The IR Agreement is for an initial term from July 25, 2024 to December 8, with a Company option to extend... Read More

Toronto, Ontario, August 29, 2024 – TheNewswire – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces, further to its press release dated August 28, 2024, that it intends to complete, subject to TSXV Venture Exchange acceptance, a non-brokered private placement of up to CDN$500,000 (the “ Offering ”) of units (“ Units ”) of the Corporation at price of $0.195 per Unit. The Offering is... Read More

Toronto, Ontario – TheNewswire - August 28, 2024 – Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Corporation " ) , ( TSXV:VPT) is pleased to provide an update on its proposed financing activities: LIFE Offering Ventripoint intends to complete, subject to TSXV Venture Exchange (“ TSXV ”) acceptance, a non-brokered private placement of up to CDN$500,000 (the “ LIFE Offering ”) of units (“ Units ”) of the Corporation... Read More

Toronto, Ontario – TheNewswire - (August 21, 2024) - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) a leader in whole heart analysis, is pleased to announce that it has received a Medical Device License from Health Canada for its latest product offering, VMS+4.0. This is a major milestone for Ventripoint as it continues to innovate and provide cutting-edge solutions to cardiac... Read More

VMS+4.0 submitted to Health Canada on July 25th for Medical Device License Ventripoint will market new advances following Health Canada approval Toronto, Ontario – TheNewswire - August 12, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) has reached another development milestone by submitting its next generation of software, VMS+4.0, to Health Canada for a Medical Device License... Read More

Toronto, Ontario – TheNewswire - July 2, 2024 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, ( TSXV:VPT) further to Ventripoint’s press release dated May 13, 2024 announcing the closing of the first tranche of the previously announced non-brokered private placement (the “ Offering ”) of unsecured debentures (“ Debentures ”) which raised gross proceeds of $941,000, Ventripoint is pleased to announce... Read More

Toronto, Ontario, June 27, 2024 – TheNewswire – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces that it will seek approval of TSX Venture Exchange (“ TSXV ” or the “ Exchange ”) to extend its previously announced non-brokered private placement (“ Offering ”) of unsecured convertible debentures (“ Debentures ”). (See press releases dated April 11, 2024, and May 13, 2024 and May 14,... Read More

Toronto, Ontario – TheNewswire - June 24, 2024 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT ) ; ( OTC:VPTDF) has been selected to present its AI-enhanced cardiac ultrasound technology, which generates MRI-quality cardiac measurements in minutes, to health-care leaders at The Data Effect on June 25 th in Vancouver. CEO Hugh MacNaught will be on the panel Accelerating AI Startups in Canadian... Read More

Toronto, Ontario – ThedNewswire - June 13, 2024 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT ) ; ( OTC:VPTDF) is delighted to welcome Matt Dobson as the company's new Marketing Director, to accelerate the company’s path to commercialization. A seasoned professional in strategic marketing, Matt brings a wealth of experience from his tenure in various marketing roles and industries, including... Read More

Toronto, Ontario – TheNewswire – June 11, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) announced a teleconference to be conducted June 14 th at which an update to shareholders will be provided. “During the first quarter we focused on effecting leadership change in the company and assessing the status of the technology, user base, operations and commercialisation. The... Read More

Toronto, Ontario – TheNewswire - May 14, 2024 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT) announces that it will seek approval of TSX Venture Exchange (“ TSXV ” or the “ Exchange ”) to extend its previously announced non-brokered private placement (“ Offering ”) of unsecured convertible debentures (“ Debentures ”). (See press releases dated April 11, 2024 and May 13, 2024). On May... Read More

Toronto, Ontario – TheNewswire - May 13, 2024 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT) announces that it has closed the insider led first tranche of its previously announced non-brokered private placement of unsecured convertible debentures (“ Debentures ”) for gross proceeds of $941,000. Ventripoint has issued an aggregate of $941,000 principal amount of Debentures with an issue... Read More

VMS+4.0 submitted to FDA on May 1 for clearance Ventripoint will market new advances after FDA clearance Toronto, Ontario – TheNewswire - May 6, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) has reached another development milestone by submitting its next generation of software, VMS+4.0, to the U.S. Food and Drug Administration (“FDA”) . This latest advance of... Read More

Toronto, Ontario – TheNewswire - May 1, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce that Duke University Health Center has purchased its second VMS+ unit from Ventripoint , which processes ultrasound images of the heart to generate MRI-quality measurements in minutes. Duke Health Center Arringdon, part of the Duke University Health System located... Read More

Toronto, Ontario – TheNewswire - April 11, 2024 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT) announces that it intends to complete, subject to TSXV Venture Exchange (the “ Exchange ”) acceptance, a non-brokered private placement of up to CDN$3,000,000 (the “ Offering ”) of unsecured convertible debentures (“ Debentures ”). Depending on market conditions, the Corporation may increase... Read More

Faster, User Friendly Cardio AI Imaging Product for Commercial Roll Out Toronto, Ont. — TheNewswire --- March 04, 2024 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT ) ; ( OTC:VPTDF) released a significant upgrade to the design and function of its whole-heart analysis system (VMS+3.2), which accelerates imaging, analysis and ease of use at the point of care. The new design allows immediate... Read More

Hamburg, Germany — TheNewswire --- February 20, 2024 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT ) ; ( OTC:VPTDF) is delighted to report its participation at the 53rd annual meeting of the German Society for Thoracic, Heart and Vascular Surgery. The event, held Feb. 19, was held in conjunction with the annual meeting of the German Society for Paediatric Cardiology and Congenital Heart Defects... Read More

Toronto, Ontario – February 13, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), ( TSXV:VPT ) ( OTCVPTDF ) announces changes to the Board of Directors. With the recent appointment of Hugh MacNaught as Interim CEO and President, the composition of board committees has been adjusted as follows: . Nominating and Corporate Governance Committee: Dr. George Adams (chair), Robert Hodgkinson, Hugh MacNaught... Read More

Toronto, Ontario – TheNewswire - February 05, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), ( TSXV:VPT ) ( OTC:VPTDF ) is pleased to announce the appointment of a new Interim CEO and President, Hugh MacNaught, who has been serving on the Ventripoint Board of Directors since 2020 and is a proven leader in biotech commercialization. As the Company enters its next phase of customer adoption and... Read More

Toronto, Ontario – TheNewswire – February 1, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF), a leader in using AI for heart imaging, is pleased to announce The Paediatric Heart Centre at the Medical University of Vienna has chosen to adopt the VMS+ as its cardiac diagnostic tool. The Paediatric Cardiology Department is part of the Children’s Heart Centre Vienna and is the... Read More

Toronto, Ontario – TheNewswire - January 29, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), ( TSXV:VPT ) ( OTC:VPTDF ) is pleased to provide 2023 in Review from the Ventripoint CEO and President, Dr. Alvira Macanovic. Dear Shareholders: I have now completed my first year as CEO and President. I’m happy to report that we had an extremely productive year at Ventripoint in 2023, with our amazing team... Read More

Toronto, Ontario – TheNewswire - January 2 1 , 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), ( TSXV:VPT ) ( OTC:VPTDF ) is pleased to announce Dr. Luc Mertens, one of Canada’s and the world’s top practitioners of echocardiography, is joining Ventripoint’s Clinical Advisory Board. Dr. Mertens, MD, PhD, is the current Section Head of Echocardiography at the Hospital for Sick Children in Toronto,... Read More

Dr. Alvira Macanovic outlines the benefits of using AI to overcome sparse data and transform ultrasound images into MRI-quality heart images Toronto, Ontario — January 3, 2024 — Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF), now bringing its AI-powered heart-scanning technology to the world’s hospitals, is delighted to release a comprehensive white paper, authored by Dr. Alvira... Read More

Hig hlights of agreement ASCEND’s IT software is used by 50,000 hospitals, clinics, and caregivers. Initial two-year term for North American markets. Ventripoint will be integrated into ASCEND’s IT for cardiovascular care. Toronto, Ontario – TheNewswire - December 12, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF), now bringing its AI-powered heart-scanning technology to... Read More

Toronto, Ontario – TheNewswire - December 05, 2023 – One of the United States’ leading foundations, the Ollie Hinkle Heart Foundation (OHHF), has selected Ventripoint’s AI-powered heart-imaging technology as one of three artificial intelligence systems it will be presenting to U.S. hospitals. Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) has pioneered an AI technology that... Read More

Toronto, Ontario – The Newswire – November 29, 2023 - Ventripoint Diagnostics Ltd. ( "Ventripoint" or the "Company" ), (TSXV:VPT ) ( OTC:VPTDF) today reported financial results for the third quarter ended September 30, 2023. Third-quarter highlights Ventripoint has successfully and seamlessly integrated its specialized AI-powered 3D Echo software application with ASCEND’s diagnostic viewer, InView, and reporting application,... Read More

Toronto, Ontario - The Newswire - November 24, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT ) ( OTC:VPTDF) is pleased to announce that it will release its third-quarter financial results and Management Discussion & Analysis for 2023 on Wednesday, November 29, 2023, after close of market. Ventripoint will host a webinar/conference call at 11:00 a.m. (EST) on Friday, December 1, 2023, to... Read More

Toronto, Ontario – TheNewswire - November 09, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is thrilled to announce it will be showcasing its AI-powered heart-imaging technology at the British Congenital Cardiac Association (BCCA) Annual Conference this year in Bristol, UK from Nov. 13 th to Nov. 14 th . As a Gold Level Sponsor, Ventripoint will have a designated booth for... Read More

Toronto, Ontario – The Newswire – November 3, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company ") (TSXV:VPT ) ( OTC:VPTDF) is pleased to announce the results of its annual general and special meeting of shareholders held on November 1, 2023, in Toronto (the " Meeting "). Shareholders voted in favour of each of the matters considered at the Meeting, including electing each of Dr. George Adams, Robert... Read More

Toronto, Ontario - TheNewswire - October 23, 2023 - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”) (TSXV:VPT ) ( OTC:VPTDF) will hold its annual general and special meeting of Shareholders (the “AGM”) on Wednesday, November 1, 2023 at 11:00 a.m. EST in a virtual-only format conducted via gotomeeting for the following purposes: To receive the audited financial statements of the Corporation; To appoint... Read More

Toronto, Ontario – The Newswire – October 12, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) has been accepted as a lead sponsor at the British Society of Echocardiography’s (BSEcho) annual conference to demonstrate its use of Artificial Intelligence to create MRI-quality model of the heart from ultrasound images. The highly anticipated hybrid conference in Cardiff, UK will... Read More

Toronto, Ontario - TheNewswire - October 3, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is pleased to announce the appointment of Mr. Jimmy Jeon as Chief Financial Officer (“CFO”) of the Company. Mr. Jeon replaces Mr. Victor Hugo, who has served as CFO since June 2020. The Company wishes to thank Mr. Hugo for fulfilling that role and to express its appreciation for his... Read More

Toronto, Ontario – TheNewswire – September 28, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF), a company using AI to create diagnostic heart images, is thrilled to announce it will be featured in an international news-style programme, “The Hidden Heart”, made possible by the British Heart Foundation and ITN Business. The programme, which documents how Ventripoint transforms... Read More

Toronto, Ontario – The Newswire – September 15, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is thrilled to announce that it will be a sponsor for the German Society for Pediatric Cardiology and Congenital Heart Defects Echo Advanced Workshop being held on September 16 th , 2023, in Bad Oeynhausen. As a sponsor, Ventripoint will have the opportunity to showcase the VMS+’s... Read More

Toronto, Ontario – The Newswire – September 13, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is thrilled to announce that it will be a sponsor for the prestigious 51 st Annual Nordic Paediatric Cardiology Meeting being held on September 13 th -15 th , 2023. The meeting will take place in Helsinki with participants from all over the world. The event is hosted by the... Read More

Toronto, Ontario – The Newswire – September 08, 2023 - V entripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is pleased to announce its participation as a Gold Sponsor for the highly anticipated 8 th Annual Paediatric Echo Society Symposium. The event will take place in Orlando, Florida on September 9 th , 2023. The Paediatric Echo Society Symposium, a nation-wide event, is staged by... Read More

Toronto, Ontario – The Newswire – August 30, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) today reported financial results for the second quarter ended June 30, 2023 ( www.sedar.ca ). Second-quarter highlights Ventripoint entered into a strategic collaboration with Ascend Cardiovascular, LLC, a leading provider of cardiovascular IT solutions and the two companies have... Read More

Toronto, Ontario – The Newswire – August 25, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is pleased to announce that it will release its second-quarter financial results for 2023 on Tuesday, August 29, 2023, after close of market. Ventripoint will host a webinar/conference call at 11:00 a.m. (EST) on Wednesday, September 6, 2023, to discuss its Q2 2023 financial results... Read More

Toronto, Ontario – The Newswire – August 22, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce that Evelina London Children’s Hospital (part of Guy's and St Thomas' NHS Foundation Trust ) is the newest user to adopt the VMS+ 3.0 system upgrade. Dr. Saleha Kabir, Lead Physiologist in Paediatrics and Advanced Echocardiography stated: "Having had... Read More

Toronto, Ontario – TheNewswire – August 18, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is thrilled to announce that Ventripoint and ASCEND Cardiovascular, LLC have developed a new integrated product. Today’s announcement marks a significant milestone in Ventripoint’s commitment to the collaboration between the two companies. ASCEND fits perfectly into Ventripoint’s... Read More

Toronto, Ontario – The Newswire – August 10, 2023 - Ventripoint Diagnostics Ltd. ( " Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is thrilled to announce that Ventripoint and Ascend Cardiovascular, a leading provider of cardiovascular IT solutions, have solidified a strategic collaboration. The two companies have signed a letter of intent to explore joint research and development initiatives, knowledge... Read More

Toronto, Ontario – The Newswire – August 2, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is thrilled to announce that it will be attending the 8 th World Congress of Paediatric Cardiology and Cardiac Surgery in Washington, DC. This is the first time the congress will be held in the continental United States. The conference will run from August 27 th , 2023 – September 1... Read More

Toronto, Ontario – The Newswire – July 18, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is pleased to announce that Freiburg Hospital has chosen to adopt the VMS+ as its cardiac diagnostic tool. The University Medical Centre Freiburg im Breisgau, Germany, is notably one of the largest hospitals in Europe and is recognized as the supra-regional centre for the treatment of... Read More

Toronto, ON - TheNewswire - July 5, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is pleased to announce that a VMS+ product has been purchased by and is fully operstional in the Deutsches Herzzentrum der Charité (DHZC), German Heart Center, in Berlin, Germany. Prof. Felix Berger, Director of the Clinic for Congenital Heart Disease – Pediatric Cardiology at DHZC stated,... Read More

Toronto, ON - TheNewswire - May 30, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is pleased to announce that it has successfully obtained European Union Medical Device Regulation (EU MDR) certification for its cardiac diagnostic system. This significant milestone further underscores Ventripoint’s dedication to delivering state-of-the-art diagnostic tools to healthcare... Read More

Ventripoint Diagnostics Ltd . (“ Ventripoint ” or the “ Corporation”) (TSXV:VPT) (OTC:VPTDF) announces that in January 2023 the Corporation granted an aggregate of 1,115,000 options to directors, officers, employees, contractors and consultants of the Corporation with an exercise price of $0.30 and with terms of 10 (ten) years and vesting from immediately to over 3 (three) years. Of these option grants, 850,000 were awarded... Read More

Toronto, Ontario – The Newswire – May 02, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) reported financial results for the fourth quarter and full year ended December 31, 2022. Highlights include: For the year ended December 31, 2022, the Company recorded revenue of $68,167. At December 31, 2022, the Company had cash and cash equivalents of $5,185,770 and a working... Read More

Toronto, Ontario – The Newswire – April 25, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTCQB:VPTDF) is pleased to announce its sponsorship of the 56th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC) being held on April 26 th -29 th 2023 in Dublin, Ireland. The AEPC is a network of specialists in the paediatric and congenital cardiology... Read More

Toronto, Ontario – TheNewswire – March 16, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to provide a corporate update on the Company’s current status and the outlook for 2023. The Company enters 2023 following an extensive period of innovation and refinement of its core technology and is now well-positioned to capitalize on those investments in creating... Read More

Toronto, Ontario – The Newswire – January 2, 2023 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Corporation "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce the appointment of Dr. Alvira Macanovic as President and CEO of the Corporation effective January 1, 2023. Dr. George Adams will continue as Executive-Chairman of the Corporation with responsibilities for new applications, investor relations and strategic... Read More

Toronto, Ontario – TheNewswire – December 14, 2022 - V entripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to provide a corporate update. Highlights Nine distributors appointed in USA to cover the entire country to join UK and European distributors for a total of 11 distributors, Sales team now has 33 sales and marketing representatives across the USA, Europe and UK, 6... Read More

Toronto, Ontario – The Newswire – November 30, 2022 - V entripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce that it has signed Arc Group Medical LLC as a distributor for the US - Florida reghion. Arc Group Medical ( www.arcgmed.com ) covers the entire Florida region and has over five years of direct cardiology sales experience and around fifteen years... Read More